Skip to main content
SpringerLink
Log in

Talimogen Laherparepvec

Onkolytische Immuntherapie des malignen Melanoms

  • panorama
  • Published:
best practice onkologie Aims and scope

Wie die Ergebnisse der OPTiM-Studie zeigen, können Patienten mit malignem Melanom in den Stadien IIIB/C oder IV möglicherweise von der onkolytischen Immuntherapie mit Talimogen Laherparepvec (T-VEC) profitieren (Kaufman HL et al., J Clin Oncol 2014, 32:5s [Suppl]:#9008a).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Satellitensymposium der Amgen GmbH

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    haf

Authors
  1. haf
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

haf Onkolytische Immuntherapie des malignen Melanoms. best practice onkologie 9, 29 (2014). https://doi.org/10.1007/s11654-014-0557-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-014-0557-3

Search

Navigation